Advancements in artificial intelligence for meibography: clinical utility and contributions to meibomian gland dysfunction management.
Authors
Affiliations (2)
Affiliations (2)
- Division of Pharmacy and Optometry, The University of Manchester, Manchester, UK.
- Johnson & Johnson MedTech, Jacksonville, FL, USA.
Abstract
Recent advances in artificial intelligence (AI) have enhanced the capabilities of meibography by enabling objective and quantitative assessment of meibomian gland structure. This review explores the clinical utility of AI-based meibography in the diagnosis and management of Meibomian Gland Dysfunction (MGD), with a focus on segmentation, morphological analysis, and disease staging. Developments in deep learning have enabled more precise gland feature extraction, including gland dropout, density, and tortuosity, supporting efforts towards standardised and reproducible clinical evaluation. Although not the focus of this review, insights from traditional image processing techniques are referenced to highlight potential areas of improvement in current AI models. Key issues such as limited modelling of regional gland variation, restricted dataset diversity, and lack of standardised image quality control are discussed. Although significant progress has been made, further work is needed to ensure AI-driven meibography tools are generalisable, interpretable, and suitable for broad clinical implementation.